Practice English Speaking&Listening with: NBC News’ Lester Holt Goes Inside Lab Creating Potential Coronavirus Treatment | NBC Nightly News

Normal
(0)
Difficulty: 0

ONE OF THE PHARMACEUTICAL COMPANIES RACING TO

PHARMACEUTICAL COMPANIES RACING TO DEVELOP VACCINES AND

COMPANIES RACING TO DEVELOP VACCINES AND TREATMENT AND OFFER

DEVELOP VACCINES AND TREATMENT AND OFFER SOME REASON FOR HOPE.

TREATMENT AND OFFER SOME REASON FOR HOPE. >>> IN A LAB NORTH OF

SOME REASON FOR HOPE. >>> IN A LAB NORTH OF NEW YORK CITY, THERE

>>> IN A LAB NORTH OF NEW YORK CITY, THERE IS PALPABLE

NEW YORK CITY, THERE IS PALPABLE ANTICIPATION THAT A

IS PALPABLE ANTICIPATION THAT A DEFENSE AGAINST EVEN

ANTICIPATION THAT A DEFENSE AGAINST EVEN TREATMENT FOR

DEFENSE AGAINST EVEN TREATMENT FOR CORONAVIRUS IS CLOSE

TREATMENT FOR CORONAVIRUS IS CLOSE AT HAND.

CORONAVIRUS IS CLOSE AT HAND. >> WE ARE OPTIMISTIC

AT HAND. >> WE ARE OPTIMISTIC BECAUSE WEVE DONE

>> WE ARE OPTIMISTIC BECAUSE WEVE DONE THIS APPROACH TO TREAT

BECAUSE WEVE DONE THIS APPROACH TO TREAT MANY HUMAN DISEASES,

THIS APPROACH TO TREAT MANY HUMAN DISEASES, SEVEN DIFFICULT TRENT

MANY HUMAN DISEASES, SEVEN DIFFICULT TRENT DISEASES.

SEVEN DIFFICULT TRENT DISEASES. >> THE COMPANY

DISEASES. >> THE COMPANY REGENERON IS TACKLING

>> THE COMPANY REGENERON IS TACKLING CORONAVIRUS.

REGENERON IS TACKLING CORONAVIRUS. >> IF YOU LOOK IN THE

CORONAVIRUS. >> IF YOU LOOK IN THE MICROSCOPE.

>> IF YOU LOOK IN THE MICROSCOPE. >> SCIENTISTS HERE ARE

MICROSCOPE. >> SCIENTISTS HERE ARE CREATING

>> SCIENTISTS HERE ARE CREATING PSEUDOCORONAVIRUS,

CREATING PSEUDOCORONAVIRUS, MEANING THE VIRUS

PSEUDOCORONAVIRUS, MEANING THE VIRUS MINUS ITS ABILITY TO

MEANING THE VIRUS MINUS ITS ABILITY TO REPLICATE, ALLOWING

MINUS ITS ABILITY TO REPLICATE, ALLOWING THEM TO LEVERAGE WHAT

REPLICATE, ALLOWING THEM TO LEVERAGE WHAT THEY BELIEVE IS THEIR

THEM TO LEVERAGE WHAT THEY BELIEVE IS THEIR SECRET WEAPON.

THEY BELIEVE IS THEIR SECRET WEAPON. MICE HOUSED IN THESE

SECRET WEAPON. MICE HOUSED IN THESE PROTECTIVE STRUCTURES,

MICE HOUSED IN THESE PROTECTIVE STRUCTURES, WHOSE IMMUNE SYSTEMS

PROTECTIVE STRUCTURES, WHOSE IMMUNE SYSTEMS HAVE BEEN GENETICALLY

WHOSE IMMUNE SYSTEMS HAVE BEEN GENETICALLY ALTERED TO MIMIC THOSE

HAVE BEEN GENETICALLY ALTERED TO MIMIC THOSE OF HUMANS.

ALTERED TO MIMIC THOSE OF HUMANS. THE BRAIN CHILD OF

OF HUMANS. THE BRAIN CHILD OF GEORGE.

THE BRAIN CHILD OF GEORGE. >> THE IDEA BEING YOU

GEORGE. >> THE IDEA BEING YOU CAN CHALLENGE THESE

>> THE IDEA BEING YOU CAN CHALLENGE THESE MICE WITH ANY DISEASE,

CAN CHALLENGE THESE MICE WITH ANY DISEASE, POTENTIALLY GET AN

MICE WITH ANY DISEASE, POTENTIALLY GET AN IMMUNE CURE.

POTENTIALLY GET AN IMMUNE CURE. >> IN A TYPICAL

IMMUNE CURE. >> IN A TYPICAL VACCINE LIKE THE FLU

>> IN A TYPICAL VACCINE LIKE THE FLU SHOT, FOR EXAMPLE, THE

VACCINE LIKE THE FLU SHOT, FOR EXAMPLE, THE OBJECTION CONTAINS A

SHOT, FOR EXAMPLE, THE OBJECTION CONTAINS A SMALL AMOUNT OF THE

OBJECTION CONTAINS A SMALL AMOUNT OF THE VIRUS TO CAUSE YOUR

SMALL AMOUNT OF THE VIRUS TO CAUSE YOUR BODY TO DEVELOP

VIRUS TO CAUSE YOUR BODY TO DEVELOP ANTIBODIES AGAINST IT.

BODY TO DEVELOP ANTIBODIES AGAINST IT. BUT THAT CAN TAKE

ANTIBODIES AGAINST IT. BUT THAT CAN TAKE WEEKS.

BUT THAT CAN TAKE WEEKS. IN THIS CASE,

WEEKS. IN THIS CASE, REGENERON ESSENTIALLY

IN THIS CASE, REGENERON ESSENTIALLY EXPOSES THE MICE TO

REGENERON ESSENTIALLY EXPOSES THE MICE TO THE PSEUDOVIRUS.

EXPOSES THE MICE TO THE PSEUDOVIRUS. THEY THEN CREATE THE

THE PSEUDOVIRUS. THEY THEN CREATE THE ANTIBODIES THAT WHEN

THEY THEN CREATE THE ANTIBODIES THAT WHEN DELIVERED TO HUMANS

ANTIBODIES THAT WHEN DELIVERED TO HUMANS PROVIDE IMMEDIATE

DELIVERED TO HUMANS PROVIDE IMMEDIATE PROTECTION.

PROVIDE IMMEDIATE PROTECTION. >> THEY ARE IN THE

PROTECTION. >> THEY ARE IN THE PROCESS OF TESTING

>> THEY ARE IN THE PROCESS OF TESTING EACH ANTIBODY TO HOW

PROCESS OF TESTING EACH ANTIBODY TO HOW WELL IT BLOCKS THE

EACH ANTIBODY TO HOW WELL IT BLOCKS THE VIRUS.

WELL IT BLOCKS THE VIRUS. OVER THE COURSE OF THE

VIRUS. OVER THE COURSE OF THE NEXT SEVERAL WEEKS,

OVER THE COURSE OF THE NEXT SEVERAL WEEKS, THEY WILL CHOOSE THE

NEXT SEVERAL WEEKS, THEY WILL CHOOSE THE BEST ONES, CREATE THIS

THEY WILL CHOOSE THE BEST ONES, CREATE THIS COCKTAIL, PUT IT IN

BEST ONES, CREATE THIS COCKTAIL, PUT IT IN THESE CELL LINES THAT

COCKTAIL, PUT IT IN THESE CELL LINES THAT CAN BE SCALED UP INTO

THESE CELL LINES THAT CAN BE SCALED UP INTO THESE GIANT VATS, AND

CAN BE SCALED UP INTO THESE GIANT VATS, AND OFF TO THE RACES.

THESE GIANT VATS, AND OFF TO THE RACES. >> ITS THE SAME

OFF TO THE RACES. >> ITS THE SAME PROCESS THEY BROUGHT

>> ITS THE SAME PROCESS THEY BROUGHT TO THE FIGHT AGAINST

PROCESS THEY BROUGHT TO THE FIGHT AGAINST EBOLA, AN ANTIBODY

TO THE FIGHT AGAINST EBOLA, AN ANTIBODY TREATMENT THAT

EBOLA, AN ANTIBODY TREATMENT THAT DRAMATICALLY BOOSTED

TREATMENT THAT DRAMATICALLY BOOSTED SURVIVAL RATES IN

DRAMATICALLY BOOSTED SURVIVAL RATES IN AFRICA.

SURVIVAL RATES IN AFRICA. >> HAVING THE

AFRICA. >> HAVING THE IMPOSSIBILITY OF

>> HAVING THE IMPOSSIBILITY OF PRODUCING SOMETHING

IMPOSSIBILITY OF PRODUCING SOMETHING THAT CAN CHANGE THE

PRODUCING SOMETHING THAT CAN CHANGE THE COURSE OF THIS

THAT CAN CHANGE THE COURSE OF THIS EPIDEMIC IS EXTREMELY

COURSE OF THIS EPIDEMIC IS EXTREMELY EXCITING.

EPIDEMIC IS EXTREMELY EXCITING. >> THE COMPANY IS

EXCITING. >> THE COMPANY IS TARGETING HUMAN

>> THE COMPANY IS TARGETING HUMAN TESTING BY LATE SUMMER

TARGETING HUMAN TESTING BY LATE SUMMER AND IS OPTIMISTIC

TESTING BY LATE SUMMER AND IS OPTIMISTIC ENOUGH THAT IT PLANS

AND IS OPTIMISTIC ENOUGH THAT IT PLANS TO SIMULTANEOUSLY

ENOUGH THAT IT PLANS TO SIMULTANEOUSLY BEGIN PRODUCING

TO SIMULTANEOUSLY BEGIN PRODUCING 200,000 PREVENTIVE

BEGIN PRODUCING 200,000 PREVENTIVE DOSES PER MONTH.

200,000 PREVENTIVE DOSES PER MONTH. >>> DO I CALL IT A

DOSES PER MONTH. >>> DO I CALL IT A MEDICATION OR A

>>> DO I CALL IT A MEDICATION OR A VACCINE YOURE WORKING

MEDICATION OR A VACCINE YOURE WORKING ON?

VACCINE YOURE WORKING ON? >> SOME PEOPLE WOULD

ON? >> SOME PEOPLE WOULD CALL THIS A PASSIVE

>> SOME PEOPLE WOULD CALL THIS A PASSIVE VACCINE.

CALL THIS A PASSIVE VACCINE. THAT IS, WE VACCINATE

VACCINE. THAT IS, WE VACCINATE THE MICE AND TAKE THE

THAT IS, WE VACCINATE THE MICE AND TAKE THE IMPORTANT PROTEIN,

THE MICE AND TAKE THE IMPORTANT PROTEIN, ANTIBODY FROM THE MICE

IMPORTANT PROTEIN, ANTIBODY FROM THE MICE AND GIVING IT TO A

ANTIBODY FROM THE MICE AND GIVING IT TO A PERSON.

AND GIVING IT TO A PERSON. ITS A VACCINE IN THE

PERSON. ITS A VACCINE IN THE SENSE THAT ITS USED

ITS A VACCINE IN THE SENSE THAT ITS USED TO PREVENT THE

SENSE THAT ITS USED TO PREVENT THE DISEASE.

TO PREVENT THE DISEASE. BUT ALSO AT HIGHER

DISEASE. BUT ALSO AT HIGHER DOSES IT CAN BE USED

BUT ALSO AT HIGHER DOSES IT CAN BE USED AS A THERAPEUTIC,

DOSES IT CAN BE USED AS A THERAPEUTIC, SOMETHING TO TREAT THE

AS A THERAPEUTIC, SOMETHING TO TREAT THE DISEASE.

SOMETHING TO TREAT THE DISEASE. >> AS YOU KNOW, THE

DISEASE. >> AS YOU KNOW, THE PHARMACEUTICAL

>> AS YOU KNOW, THE PHARMACEUTICAL INDUSTRY HAS BEEN

PHARMACEUTICAL INDUSTRY HAS BEEN UNDER FIRE FOR DRUG

INDUSTRY HAS BEEN UNDER FIRE FOR DRUG PRICES.

UNDER FIRE FOR DRUG PRICES. >> YES.

PRICES. >> YES. >> IS THIS GOING TO BE

>> YES. >> IS THIS GOING TO BE AFFORDABLE ONCE ITS

>> IS THIS GOING TO BE AFFORDABLE ONCE ITS PRODUCED?

AFFORDABLE ONCE ITS PRODUCED? >> IT DOESNT DO

PRODUCED? >> IT DOESNT DO ANYBODY ANY GOOD IN

>> IT DOESNT DO ANYBODY ANY GOOD IN THIS KIND OF SETTING

ANYBODY ANY GOOD IN THIS KIND OF SETTING OR ANY KIND OF SERIOUS

THIS KIND OF SETTING OR ANY KIND OF SERIOUS HEALTH SETTING NOT TO

OR ANY KIND OF SERIOUS HEALTH SETTING NOT TO MAKE THE PRODUCTS

HEALTH SETTING NOT TO MAKE THE PRODUCTS AFFORDABLE.

MAKE THE PRODUCTS AFFORDABLE. >> THE APPROACH IS

AFFORDABLE. >> THE APPROACH IS JUST ONE OF MANY

>> THE APPROACH IS JUST ONE OF MANY PROMISING DEVELOPMENTS

JUST ONE OF MANY PROMISING DEVELOPMENTS IN AN ALL HANDS ON

PROMISING DEVELOPMENTS IN AN ALL HANDS ON DECK EFFORT BY BIOTECH

IN AN ALL HANDS ON DECK EFFORT BY BIOTECH COMPANIES.

DECK EFFORT BY BIOTECH COMPANIES. >> THIS IS PROBABLY

COMPANIES. >> THIS IS PROBABLY THE BIGGEST MOMENT FOR

>> THIS IS PROBABLY THE BIGGEST MOMENT FOR OUR INDUSTRY IN TERMS

THE BIGGEST MOMENT FOR OUR INDUSTRY IN TERMS OF EVERYBODY IN THE

OUR INDUSTRY IN TERMS OF EVERYBODY IN THE INDUSTRY WANTING TO DO

OF EVERYBODY IN THE INDUSTRY WANTING TO DO THE RIGHT THING.

INDUSTRY WANTING TO DO THE RIGHT THING. THEY WANT TO MAKE A

THE RIGHT THING. THEY WANT TO MAKE A DIFFERENCE TO PEOPLE

THEY WANT TO MAKE A DIFFERENCE TO PEOPLE AND THEY WANT TO SHOW

DIFFERENCE TO PEOPLE AND THEY WANT TO SHOW THE WORLD.

AND THEY WANT TO SHOW THE WORLD. >> THE VACCINE, IF

THE WORLD. >> THE VACCINE, IF APPROVED, WOULD OFFER

>> THE VACCINE, IF APPROVED, WOULD OFFER SEVERAL MONTHS

The Description of NBC News’ Lester Holt Goes Inside Lab Creating Potential Coronavirus Treatment | NBC Nightly News